Drug Target Review2024-11-28T08:00:42
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2025-09-18T12:00:00
Sponsored by Benchling
2026-05-19T09:46:00
Contributor Dr Nitza Thomasson
2026-03-11T14:00:00
Sponsored by Merck
2024-02-06T08:57:06
Sponsored by bit.bio
2026-06-24T13:00:00
Sponsored by HUB Organoids
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud